Advertisements

Levolet (Levofloxacin)

Quick links to important sections

Levolet (Levofloxacin)

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Levolet (Levofloxacin)

Property Description
Active ingredient Levofloxacin
Form Tablet, Oral solution, Intravenous (IV) injection, Ophthalmic solution
Pharmacological class Fluoroquinolone Antibiotic (Quinolone)
Common use Treating various systemic bacterial infections
Origin Synthetic antibacterial agent

What is Levolet (Levofloxacin) and What Type of Medicine Is It?

Levolet is a trade name for a medicine containing the active ingredient Levofloxacin, which is a powerful synthetic antibacterial agent used to resolve infections caused by susceptible bacteria. Levofloxacin is chemically defined as the purified S-(-)-isomer of ofloxacin, distinguishing it as a single-active-ingredient product. The official classification places Levofloxacin in the Fluoroquinolone antibiotic group.

This medicine is manufactured through chemical synthesis and is designated as a prescription-only (Rx) product, reflecting its systemic nature and potency. It is available for systemic use primarily in the form of a tablet and an oral solution, as well as for direct administration via intravenous injection (infusion).


The Pharmacological Classification of Levolet (Fluoroquinolone Antibiotic)

Levofloxacin is categorized as a third-generation Fluoroquinolone antibiotic, a specialized class characterized by its broad-spectrum and bactericidal activity profile. This compound functions as a bactericidal agent, meaning its primary mechanism is designed to directly kill infectious organisms rather than merely inhibiting their growth.

Levofloxacin is used to treat a wide variety of bacterial infections and works by killing bacteria or preventing their growth. This functionality makes it a common choice in clinical practice for managing serious conditions, such as community-acquired pneumonia. This general benefit indicates the medicine’s primary function is to halt the advance of an active infection by eliminating the responsible pathogens.


General Purpose: Why Levofloxacin is Used

The general purpose of Levofloxacin is to effectively combat and resolve established bacterial infections throughout the body by eliminating the organisms susceptible to its action. The medicine's utility is confined strictly to conditions proven to be caused by bacteria, utilizing its specific bactericidal mechanism to interrupt essential microbial life processes. It is fundamentally intended to stop the progression of an illness caused by a microbial invasion, supporting the body’s recovery.

Regulatory References

  1. NIH
Advertisements

What side effects are possible with Levolet (Levofloxacin)?

Possible side effects and safety information

The safety profile of Levofloxacin is structured by regulatory documents that classify adverse reactions based on their frequency and the affected System-Organ Class (SOC). Common effects, as listed in the prescribing information, typically include gastrointestinal issues such as nausea and diarrhea, and central nervous system effects like headache and insomnia.

Reactions classified as Uncommon involve symptoms such as vomiting, abdominal pain, dizziness, rash, and transient increases in liver enzymes. Rare adverse reactions include the development of tendinitis, paresthesia, psychotic disorders, tremor, and hypotension.

Serious Adverse Reactions and Safety Constraints

The official labeling highlights several serious adverse reactions associated with the fluoroquinolone class. These include the risk of Tendinitis and potentially irreversible Tendon Rupture (which may occur during or months after treatment), and Peripheral Neuropathy (nerve damage). Other serious documented risks are QT Interval Prolongation (affecting heart rhythm), Aortic Aneurysm and Dissection, severe Hypersensitivity Reactions, and Clostridium difficile-associated diarrhea (CDAD).

Regulatory documents establish safety limitations for specific groups. The medicine is generally contraindicated in patients with a history of tendon disorders related to previous quinolone use and in those with epilepsy. Older adults have an increased susceptibility to tendinopathy and QT prolongation. Levofloxacin is typically contraindicated in pediatric patients due to concerns over joint damage.

Advertisements

Overdose and Emergency Response

Overdose Scope

Property Official Regulatory Statement
Documented overdose presentations Acute Central Nervous System (CNS) manifestations, including Convulsions (Seizures), Tremors, Confusion, and Dizziness. Non-specific symptoms such as Nausea and Vomiting are also commonly observed.
Physiological systems affected (as stated in label) Primarily the Central Nervous System and Cardiovascular System, specifically its electrical activity.
Dose-related or exposure-related factors (if applicable) Overdose is associated with exaggerated, high-dose CNS effects and the potential for severe cardiac risk due to elevated plasma concentrations.
Population-specific overdose notes (if applicable) Clearance is substantially reduced in patients with Renal Impairment, leading to drug accumulation and a prolonged elimination half-life.
Emergency-response statements (as written in official documents) Treatment is mandated to be symptomatic and supportive. Procedures should include considering Activated Charcoal administration to limit gastrointestinal absorption.
When immediate medical help is required (label-derived phrasing only) Seek immediate medical attention or contact a physician or emergency services immediately upon suspicion of overdose.

Overdose Classifications (High-Level)

Property Official Regulatory Statement
Severity classification (as defined in official documents) Overdose may be associated with life-threatening cardiac events (Torsade de pointes) and severe CNS toxicity.
Regulatory basis (EMA / FDA / etc.) U.S. Food and Drug Administration (FDA) Prescribing Information and European Medicines Agency (EMA) Summary of Product Characteristics (SmPC) equivalents.
Overdose-context constraints (as defined in official documents) No specific antidote is known; the drug is not efficiently removed by dialysis.

Resulting Overdose Structure

Official overdose statements:

  • Overdose may lead to severe CNS manifestations, including convulsions and tremors, necessitating urgent medical evaluation.
  • The regulatory label documents the risk of Prolongation of the QT interval and, in isolated instances, Torsade de pointes.
  • Due to the lack of a specific antidote, regulatory guidance mandates symptomatic and supportive treatment, including continuous ECG monitoring for cardiac stability.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents strictly define the Levofloxacin overdose profile by focusing on acute CNS toxicity and cardiac electrical risk. The required emergency action is dictated by the potential for life-threatening events like severe arrhythmias and seizures, leading to the official mandate to seek immediate medical attention. The profile establishes that management is symptomatic and supportive, with specific mention of ECG monitoring and the limited benefit of dialysis.

Advertisements

Therapeutic Uses of Levolet (Levofloxacin)

Levofloxacin is commonly used to treat a variety of bacterial infections across different organ systems. This medicine is relevant in clinical settings where supportive symptom management is appropriate for serious conditions.

Targeting Severe Lower Respiratory and Systemic Illnesses

Levofloxacin is applied in addressing conditions characterized by periods of heightened symptoms, including serious lung infections (Community-Acquired Pneumonia, acute flare-ups of Chronic Bronchitis), and complicated infections in the urinary system (Acute Pyelonephritis, Chronic Bacterial Prostatitis). It is applied in addressing symptom clusters such as high fever, severe cough, and localized intense pain that interfere with functional stability.

Applied in Serious Skin Infections and High-Risk Exposure Contexts

It is also applied in addressing complicated infections of the skin and underlying soft tissues. Furthermore, Levofloxacin is applied in specialized contexts for the post-exposure prevention and treatment of highly dangerous bacterial threats, notably Inhalational Anthrax and the Plague. It supports patients during difficult episodes by easing distress.

Quick Fact: Use in Managing Localized Pain and Fever Levofloxacin is commonly used to help with managing systemic and localized discomfort associated with serious bacterial infections, which assists with maintaining functional stability.

Regulatory References

  1. NIH MedlinePlus overview of Levofloxacin uses
Advertisements

Eligibility and Restrictions for Use

Levofloxacin eligibility is strictly defined by official regulatory bodies, focusing on population-specific exclusions and restrictions. The medicine is contraindicated for patients with a known hypersensitivity to levofloxacin, any other quinolone antimicrobial, or those with a history of tendon disorders related to prior fluoroquinolone use. It is also prohibited for patients diagnosed with epilepsy.

Population Group Eligibility Status
Pregnancy/Lactation Contraindicated
Children/Adolescents Contraindicated for routine systemic use (generally under 18)

Adults (18 years) are generally eligible. Use in children (6 months) is an exception, approved only for specific, severe conditions such as Inhalational Anthrax and Plague.

Eligibility is restricted for several conditions. Patients with impaired renal function (Creatinine Clearance leq 50 mL/min) are eligible but require official dose adjustment. Use is typically avoided in patients with a history of myasthenia gravis due to the risk of exacerbating muscle weakness. Special caution is necessary for older adults (60 years) and patients concurrently taking corticosteroids or those with cardiovascular risk factors (e.g., QT prolongation) due to heightened risk.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Levofloxacin is defined by three primary regulatory concerns: altered absorption, reduced clearance, and reinforced pharmacodynamic risk.

Co-administration with multivalent cation-containing products, such as antacids (magnesium/aluminum), Sucralfate, iron salts, or zinc salts, significantly decreases the oral absorption of Levofloxacin due to chelation. Regulatory documents mandate that oral Levofloxacin must be administered at least 2 hours before or 2 hours after these products, and the intravenous formulation must not be mixed with any multivalent cation solution.

Substances that inhibit renal tubular secretion, including Probenecid and Cimetidine, officially result in a reduction of Levofloxacin renal clearance, thereby increasing the drug's plasma exposure.

Regulatory agencies also highlight critical pharmacodynamic interactions. The label advises avoiding use with medicines that prolong the QT interval due to the risk of additive cardiac effects. The co-administration of Levofloxacin with corticosteroids carries an officially stated increased risk of tendinitis and tendon rupture.

Furthermore, concomitant use with Vitamin K antagonists (e.g., Warfarin) may enhance the anticoagulant effect, requiring close monitoring. Similar monitoring of blood glucose is required when Levofloxacin is used with antidiabetic agents.

Advertisements

Mechanism of Action

Targeted Inhibition of Bacterial DNA Topoisomerases

Levofloxacin acts by directly and specifically inhibiting two bacterial enzymes: DNA Gyrase (Topoisomerase II) and Topoisomerase IV. These enzymes are essential for managing the physical structure of the bacterial DNA during processes like replication and division. Levofloxacin achieves this by binding to and stabilizing the cleaved DNA-enzyme complex, effectively trapping the enzyme and preventing the vital re-ligation of the DNA strands. This specialized binding mechanism introduces structural failure into the bacterial cell's DNA management process.


Lethal Cascade and Cessation of Pathogen Proliferation

The structural stabilization causes the accumulation of double-strand DNA breaks in the bacterial genome. Simultaneously, the inhibition of Topoisomerase IV physically blocks the separation of newly copied chromosomes (decatenation). The combination of accumulated DNA damage and division failure exceeds the capacity of the bacteria's natural repair mechanisms, resulting in cellular death (bactericidal action). This physiological effect is defined as the direct killing of the susceptible microbial cell.

Advertisements

Dosage and Administration Information

How to Use Levolet (Levofloxacin): Administration Guidelines

Levofloxacin is administered according to strict dosage and timing instructions to ensure proper antibacterial effectiveness. The medicine is available for systemic use via oral and intravenous (IV) infusion routes, with an additional ophthalmic solution for localized eye treatment.

Routes and Administration Specifics

Administration Route Instructions for Use
Oral Tablet May be taken with or without food. Swallow whole.
Oral Solution Should be taken 1 hour before or 2 hours after eating.
Intravenous (IV) Must be administered as a slow infusion over 60 minutes (500 mg dose) or 90 minutes (750 mg dose).

Standard Dosing and Duration

The typical adult dosing frequency for Levofloxacin is once daily (every 24 hours). The maintenance dose ranges from 250 mg to 750 mg, with duration precisely defined by the specific infection, such as 3 days for uncomplicated urinary tract infections or up to 60 days for Inhalational Anthrax post-exposure treatment.

Required Dose Adjustments and Timing

Renal Impairment: A dose reduction or interval extension (e.g., 750 mg every 48 hours) is required for adults with a Creatinine Clearance (CrCl) of less than 50 mL/min. Cation Separation: Oral forms must be taken at least 2 hours before or 2 hours after products containing multivalent cations (e.g., iron, zinc, antacids) to prevent reduced absorption.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Levolet (Levofloxacin)

Evidence for Use in Lower Respiratory Tract Infections

Research on Levofloxacin for conditions such as Community-Acquired Pneumonia primarily relies on large-scale, multi-center Randomized Controlled Trials (RCTs) and systematic reviews. The studies were designed to assess whether Levofloxacin's measured outcomes were within a pre-defined margin of the comparator drugs. Study populations focused mainly on adults, from mild to severe infections requiring hospital admission. Trials reported measurements related to how infection signs evolved and the rates of microbiological eradication of the targeted bacteria. The short-term treatment phases usually ranged from five to fourteen days.

Evidence for Use in Urinary Tract and Prostate Infections

Studies for infections like complicated Urinary Tract Infections (cUTI) and Acute Pyelonephritis included randomized, active-controlled clinical trials. Research explored the comparability of shorter treatment courses (e.g., five days) against longer, conventional durations. The studies measured clinical response rates and achieving microbiological clearance in adults with complicated infections. For Chronic Bacterial Prostatitis, research monitored potential microbiological clearance and symptom evolution over a longer course, often studied over twenty-eight days.

Evidence for Use in Skin/Soft Tissue Infections and Highly Specialized Contexts

For complicated Skin and Soft Tissue Infections, non-inferiority trials monitored clinical success rates and measures related to microbiological clearance over periods of seven to fourteen days in adult populations. For highly specialized contexts such as Inhalational Anthrax and Plague, direct human efficacy trials are not feasible. Research relies on animal efficacy studies (examining survival outcomes) and Pharmacokinetic/Pharmacodynamic (PK/PD) bridging studies in human volunteers, requiring reliance on animal models and extrapolation.

Key Limitations and Uncertainties in the Research Landscape

A large part of the clinical evidence is based on non-inferiority trials, meaning research was not structured to describe superior performance against other treatment options. Evidence quality varies across studies, and findings were mixed regarding certain specific comparative outcomes. Long-term outcomes, such as sustained symptom resolution or recurrence rates beyond the acute follow-up period, are not consistently characterized across all existing studies. Data for certain groups, such as those with complex comorbidities or specific immune system disorders, remain insufficient.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Levolet (Levofloxacin) (FAQ)

Q: Can Levolet cause light sensitivity or increase the risk of sunburn?

A: Yes, official product information indicates that levofloxacin is associated with increased sensitivity to sunlight (photosensitivity). This can make a person susceptible to severe sunburn even after only brief sun exposure. Regulatory documents suggest minimizing exposure to the sun and artificial UV light while using this medication.

Q: Does Levolet interact with common pain relievers like ibuprofen?

A: The official product label does not specifically name ibuprofen. However, regulatory warnings note that taking other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) alongside levofloxacin may potentially increase the risk of certain side effects affecting the Central Nervous System, such as seizures. The combined use of these types of medications should be reviewed with a healthcare provider.

Q: Is it normal to feel a little dizzy or lightheaded after taking Levolet?

A: Yes, dizziness is listed in regulatory documents as a common side effect of levofloxacin. Because the medication can affect alertness and coordination, it can contribute to feelings of lightheadedness. Official information advises exercising caution with activities that require full mental alertness.

Q: What are the signs of a serious allergic reaction to Levolet that people talk about?

A: According to the FDA Medication Guide, symptoms of a severe allergic reaction can include hives, trouble breathing or swallowing, swelling of the lips, tongue, or throat, and fainting. Should any signs of a severe reaction occur, seeking emergency medical attention is necessary.

Q: Can Levolet affect sleep patterns, like causing insomnia?

A: Yes, regulatory documents list insomnia, or difficulty sleeping, as one of the common side effects of levofloxacin.

Q: What distinguishes Levolet from amoxicillin or penicillin-type antibiotics?

A: Levofloxacin belongs to the Fluoroquinolone class of antibiotics, which has a distinct mechanism of action. Unlike penicillin-type antibiotics, levofloxacin works by directly blocking the bacteria’s DNA synthesis, which results in the direct killing of the microbial cells.

Q: What precautions should be taken regarding physical activity while using Levolet?

A: Official warnings advise caution regarding physical activity due to the risk of tendinitis and tendon rupture. If tendon pain or swelling is experienced, official information indicates the need to rest the affected area and consult a healthcare provider about stopping the medication. This risk can occur during or months after treatment is finished.

Q: Why is Levolet sometimes used for children, and what are the concerns?

A: Routine systemic use of levofloxacin is generally contraindicated (not recommended) in children and adolescents due to concerns about potential joint damage. However, regulatory exceptions allow its use for specific, severe, and life-threatening infections in children over 6 months old, such as post-exposure to Inhalational Anthrax.

Q: What is the significance of finishing the entire course of Levolet, even if feeling better?

A: Official guidance emphasizes that patients should take all of their medication as prescribed and avoid stopping early, even if symptoms have improved. This is necessary to ensure the infection is completely cleared and to help prevent the development of drug-resistant bacteria.

Q: What is the typical length of time a person takes Levolet for?

A: The required duration of treatment varies widely and is precisely defined by the specific type and severity of the infection being treated. Official dosing schedules can range from short courses of 3–5 days for some infections to longer courses of 28 days or more for chronic conditions.

Q: Are there any common foods or drinks that should be avoided while on Levolet?

A: While the oral tablets can be taken with or without food, regulatory information highlights that products containing multivalent cations (like iron and zinc supplements, or antacids) must be avoided at the same time. These products should be taken at least two hours before or two hours after the oral levofloxacin dose to prevent reduced absorption.

Q: Is Levolet known to cause gastrointestinal issues like diarrhea?

A: Yes, official product information lists diarrhea as one of the common side effects associated with taking levofloxacin.

Q: Does Levolet interact with mineral supplements, like calcium or iron?

A: Yes, the official label explicitly states that the absorption of oral levofloxacin is significantly decreased if taken too close to iron salts and zinc salts. Regulatory guidance mandates a two-hour separation between taking oral levofloxacin and any product containing these multivalent cations.

Q: What should be done if a dose of Levolet is missed?

A: Official patient resources provide guidance for missed doses, which generally involves taking the dose when remembered unless it is nearly time for the next scheduled dose. Specific instructions should be followed as directed by the prescribing professional.

Q: Do people often report feeling 'foggy' or having trouble concentrating while taking Levolet?

A: Regulatory warnings highlight that levofloxacin can cause Central Nervous System effects, which may include symptoms like confusion, anxiety, restlessness, and trouble sleeping. These effects could contribute to a feeling of mental 'fogginess' or reduced concentration.

Q: Are there any non-prescription medications or supplements that commonly interact with Levolet?

A: Yes, the absorption of the oral form is strongly affected by over-the-counter products containing multivalent cations, such as antacids that contain magnesium or aluminum, and certain iron or zinc supplements. These must be separated by two hours from the antibiotic dose.

Q: Can Levolet cause yeast infections as a secondary effect?

A: As with many antibiotics, levofloxacin use can potentially lead to secondary infections, such as fungal (yeast) infections. This is due to the drug changing the normal balance of bacteria in the body.

Q: Can Levolet interfere with birth control pills?

A: Some regulatory resources suggest that antibiotics, including levofloxacin, may potentially reduce the effectiveness of estrogen-containing oral contraceptives in some women. Specific guidance on contraception while on this medication should be reviewed with a healthcare provider.

Q: Why do some people experience ringing in the ears (tinnitus) with Levolet?

A: Ringing in the ears, known as tinnitus, has been reported in clinical trials and is sometimes associated with this class of antibiotics. While it is not listed as a common side effect in the main product information, it is a known possible adverse reaction.

Q: Are there guidelines for driving or operating machinery while taking Levolet?

A: Yes, official regulatory warnings advise patients not to drive, operate heavy machinery, or participate in activities requiring full concentration until they are certain how the medication affects them, as it may cause dizziness, reduced alertness, or lightheadedness.

Q: What are the warning signs of a C. difficile infection that can be linked to Levolet?

A: Clostridium difficile-associated diarrhea (CDAD) is a serious risk associated with the use of levofloxacin. Warning signs include severe diarrhea that may be watery or bloody, fever, and severe stomach cramping. These symptoms can occur during treatment or up to two months after stopping the medication.

Q: Does taking Levolet affect the results of any standard laboratory tests?

A: Yes, regulatory documents indicate that levofloxacin can interact with certain laboratory tests. Specifically, it can cause false-positive results in urine drug screenings for opiates and may also affect blood glucose (sugar) measurements in patients with diabetes.

Q: Can Levolet interact with caffeine or energy drinks?

A: Levofloxacin may potentially interfere with the body's ability to clear caffeine, which is found in coffee and energy drinks. This can lead to increased nervousness, jitteriness, or anxiety from the caffeine, so caution is generally advised.

Q: Does Levolet have a black box warning, and what does it relate to?

A: Yes, levofloxacin, as a fluoroquinolone antibiotic, carries a Boxed Warning from the FDA. This warning highlights the risk of serious side effects, including tendinitis and tendon rupture, permanent peripheral neuropathy (nerve damage), and severe effects on the Central Nervous System.

Q: Is it common for Levolet to cause temporary changes in vision?

A: Temporary changes in vision, including blurred vision, have been reported as serious side effects. Patients taking the ophthalmic (eye drop) form have also reported decreased vision. If vision changes occur, a healthcare provider should be consulted for evaluation.

Q: How should dairy products be timed in relation to taking Levolet?

A: While the oral tablet can be taken with or without food, some guidance suggests separating the dose from dairy products and calcium-fortified juices by two or more hours. This precaution is advised because calcium, similar to other multivalent cations, may interfere with the full absorption of the medication.

Q: What is the general consensus on Levolet's effectiveness for sinus infections?

A: Levofloxacin is officially approved for the treatment of Acute Bacterial Sinusitis. However, due to the risks associated with the fluoroquinolone class, regulatory bodies recommend reserving its use for this condition when other treatment options are not suitable.

Advertisements

How should Levolet (Levofloxacin) be stored and disposed of?

How to Store and Dispose of Levofloxacin

Levofloxacin tablets and oral solution must be stored at controlled room temperature, maintaining 20 C to 25 C (68 F to 77 F). The medicine must be kept in a well-closed container and protected from freezing, excessive heat, and light. The intravenous injection premix may be stored at controlled room temperature or under refrigeration.

Child-Safety and Disposal

All forms of this medicine must be kept out of the reach of children. Unused or expired levofloxacin should be disposed of through a drug take-back program when available. If a program is not accessible, the product must be removed from its container, mixed with an undesirable substance like dirt or used coffee grounds, sealed in a bag, and then placed in the household trash. Levofloxacin must not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Levolet (Levofloxacin) found in:

A-Z Index: